Targeted therapy shows benefit for people with advanced breast cancer in late-stage trial

An experimental treatment shows promise for people with the most common form of advanced-stage breast cancer, according to results from a Phase 3 clinical trial.The details of the trial were presented Thursday at the San Antonio Breast Cancer Symposium.It showed that AstraZeneca's capivasertib  in combination with Faslodex (fulvestrant), an endocrine therapy already used to treat advanced breast cancer  gave people a median of 7.2 months without disease progression, compared with 3.6 months in people who got a placebo plus the endocrine therapy.

Read at www.cnn.com